FDA rejects saxa dapa
- Thread starter anonymous
- Start date
-
- Tags
- None
<
you go first. Do your own homework. Doesn't take much to figure it out
FDA denial + Crestor loss of exclusivity + so-called Enterprise Years = big layoffs coming soon
You're sick in the head Libre FDA Boy ....Get your ass back to Abbvie /Abbott board you sick F'k
Problem is Onglyza has heart failure issues and Farxiga has cancer issues,bladder. This is not a safe combo but BI and Lilly already have the combo. This is a significant setback. BMS is happy to be out of diabetes This combo is dead on arrival or should we say no arrival
You are correct AZ did fuck this up. Remember they did not get Farxiga on the first try either. Tried to get by with less data. Business community is coming down hard on AZ with this non approval.Look at what is happening. Put everyone on Bydureon that is now our future. This will signicantly hurt when the competitors start bringing up this latest FDA decision
Did the FDA not approve the drug. I thought it was a no brainier that it would get approved. How can this be?
WHEN IS THE BOARD GOING TO FIRE OUR DUMBASS CEO! HE IS POISON TO AZ! HE IS RESPONSIBLE FOR FAILURE AFTER FAILURE! HE NEEDS TO GO NOW!!!
all 3 diabetes products suck.
onglyza- 1% market share
bydoureon- 2% market share
farxiga 20% market share
fda will never approve combo and if it happens, no one will write the combo because of onglyza.
out of my 150 drs only 3 write onglyza
onglyza- 1% market share
bydoureon- 2% market share
farxiga 20% market share
fda will never approve combo and if it happens, no one will write the combo because of onglyza.
out of my 150 drs only 3 write onglyza
My Bydureon market share is close to 30%...ummm...you suck as a rep dude!!
This happens to AZ all of the time. Bad Karma from HR policies.
Iressa, Galida, Recentin, Exanta, Zactima, Remember the chart that depicted two launches a year?
But you are a legend. You and a few others can sell. The rest of us are stuck with Onglyza and Farxica. What a diabetes portfolio
Do not fret. The combo will be out in a year
The sad news is Farxiga will only generate 400 million dollars this year. Onglyza 600 million. Neither is hardly a blockbuster. What is Invokana's forecast. I would think north of a billion. Farxiga with all their discounts have not really dented the market. And Jardiance should take some share with the CV data. Farxiga is in trouble nationally it would appear. This latest setback with saxadapa will not help.
So no new product.
Crestor going generic.
Some Primary Care selling Farxiga. Why not just give Onglyza to them also?
Then combine oral and injectable and get rid of all the extra managers... At least half of the useless mangers!!
Crestor going generic.
Some Primary Care selling Farxiga. Why not just give Onglyza to them also?
Then combine oral and injectable and get rid of all the extra managers... At least half of the useless mangers!!